AI assistant
PFIZER INC — Director's Dealing 2018
Jan 3, 2018
29831_dirs_2018-01-03_4d7ea848-7cee-4fa4-8def-b9e05db873d2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2017-12-29
Reporting Person: READ IAN C (Director, Chairman & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-29 | Stock Appreciation Rights | $36.2200 | A | 1372213.0000 | Acquired | 2022-12-29 | Common Stock (1372213.0000) | Direct |
Footnotes
F1: The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through March 31, 2019 (or such earlier time as determined by the Board of Directors) and he is either employed by Pfizer or is subject to. and complies with a non-compete and non-solicitation agreement until March 31, 2021 and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022).